iBio (IBIO) Stock Is Already Soaring Amid Settling Oncology Drug Discovery Pipeline with Three New Antibody Programs

For the last 30 days, iBio’s stock was mainly declining. Yesterday, the stock reached $1.33 point. However, today after great news it is starting to surge. In pre-market it is expected to be $1.48, which results in a good 11% boost. The company has taken another major step towards increasing the speed and performance of its patented FastPharming Protein Expression System®, a plant-based protein expression system, announcing today the addition of three cancer targets to its therapeutic candidate portfolio.

This development opens up new opportunities for the company to discover new drugs, which were announced just a few weeks ago. As part of iBio’s efforts to transform the drug development paradigm with FastPharming by reducing the time and cost of moving from initial concept to clinic, the company intends to partner with best-in-class technology partners to help realize this vision.

Accordingly, iBio entered into a research services agreement with FairJourney Biologics S.A. (“FairJourney”), a leader in antibody optimization. Under the agreement, iBio will have access to new imaging technologies and proprietary antibody libraries.

Jack Dawkins

Finance and Tech Contributor